MedTrace Logo

External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

NCT04697446 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 279

Last updated 2021-08-10

No results posted yet for this study

Summary

This is an external control, observational, retrospective study designed to compare clinical outcomes for pralsetinib compared with best available therapy for patients with RET-fusion positive advanced NSCLC.

Conditions

  • RET-fusion Non Small Cell Lung Cancer
  • Lung Neoplasm
  • Carcinoma, Non-Small-Cell Lung
  • Respiratory Tract Neoplasms
  • Thoracic Neoplasms
  • Neoplasms by Site
  • Neoplasms
  • Lung Diseases
  • Respiratory Tract Diseases
  • Carcinoma, Bronchogenic
  • Bronchial Diseases
  • Head and Neck Neoplasms
  • Carcinoma
  • Neoplasms by Histologic Type
  • Neoplasms, Germ Cell and Embryonal
  • Neoplasms, Nerve Tissue
  • Metastatic Non Small Cell Lung Cancer

Sponsors & Collaborators

  • Analysis Group, Inc.

    collaborator INDUSTRY

  • Blueprint Medicines Corporation

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-10-31
Completion
2021-10-31

Countries

  • United States
  • France
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04697446 on ClinicalTrials.gov